Trientine manufacturer and drug source

Trientine(Trientine), also known as triethylaminetetraacetic acid, is a metal chelator mainly used to treat Wilson's disease, a rare genetic disease caused by copper metabolism disorder. As a second-line treatment drug, trientine is suitable for patients who are intolerant to penicillamine. Its mechanism of action is to form a soluble complex with excess copper in the body and then excrete it through urine, thereby reducing the accumulation of copper in the body.

At present, the internationally well-known original drug Trientine was first developed by the French company Pharmaceutiques du Lude, and is sold in the European and American markets by pharmaceutical companies such as Rare Disease Therapeutics and Univar Solutions in the United States. Commonly sold under the trade name Syprine®, commercialization rights for the U.S. market are held by Valeant Pharmaceuticals International (now Bausch Health). In addition, in the European market there are original research versions produced by pharmaceutical companies in Germany and other countries, which are widely used in the clinical path of treating Wilson's disease.

Since trientine is an orphan drug for rare diseases, its R&D and production thresholds are high. In addition, the number of patients worldwide is small and the market size is relatively limited. Therefore, no local pharmaceutical company in China has successfully copied the drug. Some pharmaceutical companies in India have started R&D and market supply of generic trientine drugs. Although it has not been widely certified by mainstream European and American markets, its price advantage has made it the focus of many patients seeking substitute drugs. Global procurement, cross-border medical treatment and other channels have become important ways to obtain this drug.

In summary, trientine, as an important therapeutic drug, plays an important role in the treatment of hepatolenticular degeneration. Trientine is an effective treatment for Wilson's disease. Its manufacturers are gradually increasing and its market supply is expanding. It is expected to help more patients in the future.

Reference materials:https://www.cufence.com/